Clinical trial · Observational
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
An Observational Phase IV Non Interventional Study in Patients With Advanced Follicular Lymphoma (III-IV) Evaluating the Safety of Maintenance Therapy With Rituximab After 8 Cycles of Rituximab in Combination With Chemotherapy as Induction Therapy in Previously Untreated Patients in Greece.
NCT01609036CI-TRIAL-00024614terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Follicular | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Safety: Incidence of adverse events
- timeFrame
- 3 years
Secondary outcomes (3)
- measure
- Progression-free survival
- timeFrame
- 3 years
- measure
- Event-free survival
- timeFrame
- 3 years
- measure
- Overall survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/=18 years * Patients with previously untreated follicular lymphoma (stage III-IV) according to the approved summary of product characteristics (SPC) Exclusion Criteria: * Contraindications to MabThera/Rituxan therapy according to the approved SPC
References
Publications (0)
Data not yet available
No reference posted for this study.